Key mechanisms include the livers role in clearing peripheral -amyloid (A), the influence of hepatic enzymes and metabolites on cognitive decline, and the systemic effects of metabolic disorders on AD progression
What the research shows: In the landmark STEP clinical trials, patients taking semaglutide lost an average of 15% of their body weight over 68 weeks
GLP-1s and cancer: promising but no clinical trial evidence Obesity is a risk factor for at least 13 cancers, so reducing weight using GLP-1 drugs can also be expected to limit cancer risk
Congenital hypothyroidism caused by excess prenatal maternal iodine ingestion
2014;371(23):22006 The authors administered an inhibitor of APOC3 mRNA to treat three patients with the familial chylomicronemia syndrome and severe hypertriglyceridemia
Thats not to say one is better than the otherit all depends on your goals, health history, and what your body responds to